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LETTER TO THE EDITOR
Surveillance or etoposide-containing combination chemotherapy for stage
I non-seminomatous germ cell tumours of the testis (NSGCTT)
Sir - I note with interest that Dr Cullen and co-workers have
presented a case for consideration of immediate adjuvant
chemotherapy in preference to surveillance for patients with
clinical stage I NSGCTT (Cullen et al., 1994). They point out
that surveillance followed by chemotherapy for those who
relapse and adjuvant chemotherapy for all (two courses of
bleomycin, etoposide and cisplatinum) are both capable of
achieving a near-perfect outcome in the management of such
patients. They have questioned their patients and reached the
conclusion that surveillance is not a popular option and that
it might be preferable to offer adjuvant combination
chemotherapy (including etoposide) to all clinical stage I
NSGCTT patients.
Were such treatment to be free of significant long-term
adverse effects this advice might be sound. However, by
chance, an adjacent abstract in the March supplement of the
British Journal of Cancer, from the Royal Free, Royal
London and Charing Cross Hospitals, raises the spectre of
carcinogenic long-term adverse effects of etoposide. In this
paper, Boshoff et al. (1994) remind us that non-etoposide-
containing regimens, such as PVB and POMB, do not appear
to be associated with an increased risk of subsequent
leukaemia. On the other hand, etoposide-based regimens do
have this potential.
Nichols et al. (1993) have shown that there is a small
increase in the incidence of leukaemia in germ cell testicular
patients who have been treated with etoposide, but this is not
seen in those treated with non-etoposide-containing regimens
(Nichols et al., 1985). Kumar (1993) has observed that a total
cumulative dose of etoposide (greater than 2 g m-2) and
concomitant administration of drugs that inhibit DNA repair
are associated with an increased risk.
Two cycles of standard BEP will expose patients to a total
cumulative dose of etoposide of only 720 mg m-2, but both
bleomycin and cisplatinum damage DNA and are capable of
inhibiting its repair. Thus, subsequent leukaemia in some
patients following even only two cycles of BEP would not be
entirely unexpected. It would be most unfortunate if a
patient who was not likely to relapse subsequently developed
a cancer secondary to such adjuvant treatment. One would
have to question the wisdom of such a treatment on an
adjuvant, as opposed to a therapeutic, basis.
The secondary leukaemias seen in patients previously
treated with etoposide-containing chemotherapy seem to
occur in the first decade after their treatment, much in the
same way as secondary leukaemias have been noted follow-
ing the successful treatment of Hodgkin's disease with
alkylating agents. In these patients we are now becoming
aware that in subsequent decades there seems to be an in-
creased incidence of secondary solid tumours and alkylating
agents appear to be implicated (Boice, 1993). It would be of
very great concern if this sequel were to be reproduced in
patients cured of their NSGCTT by etoposide-containing
combinations.
Consequently, I believe that it would be unwise to promul-
gate the hypothesis that surveillance be replaced by the ex-
hibition of potentially dangerous and often unnecessary
adjuvant chemotherapy. By extension of this concept one
might also question the wisdom ofusing BEP instead of PVB
or other non-etoposide-containing regimens in the manage-
ment of metastatic testicular cancer. Along with others, we in
Christchurch, New Zealand, discarded PVB some years ago
in favour of BEP because of the unpleasant adverse effects of
vinblastine. However, unpleasant as they were, they may well
be preferable to subsequent carcinogenesis.
I would be interested to hear the views of Dr Cullen and
his colleagues on the issues raised in this letter.
Yours etc,
B.M. Colls
Department of Medicine
The Christchurch School of Medicine
Christchurch Hospital
Christchurch, New Zealand, PO Box 43345
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